The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Two new PD-(L)1 x VEGF projects have entered the clinic.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
Ideate-Lung02 goes on global clinical hold.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
